Citation: | Please cite this article as: M Verdoia, R Gioscia, G D Luca. Optimal dual antiplatelet therapy strategy in elderly patients with acute coronary syndrome. J Geriatr Cardiol 2021; 18(3): 210−218. DOI: 10.11909/j.issn.1671-5411.2021.03.010 |
[1] |
Bortnick AE, Epps KC, Selzer F, et al. Five-year follow-up of patients treated for coronary artery disease in the face of an increasing burden of co-morbidity and disease complexity. Am J Cardiol 2014; 113: 573−579. doi: 10.1016/j.amjcard.2013.10.039
|
[2] |
Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol 2014; 63: 747−762. doi: 10.1016/j.jacc.2013.09.070
|
[3] |
De Luca G, van't Hof AW, Ottervanger JP, et al. Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Eur Heart J 2005; 26: 662−666. doi: 10.1093/eurheartj/ehi110
|
[4] |
Kayani WT, Khan MR, Deshotels MR, Jneid H. Challenges and controversies in the management of ACS in elderly patients. Curr Cardiol Rep 2020; 22: 51. doi: 10.1007/s11886-020-01298-x
|
[5] |
De Luca G, Dirksen MT, Spaulding C, et al. Impact of age on long-term outcome after primary angioplasty with bare-metal or drug-eluting stent (from the DESERT cooperation). Am J Cardiol 2013; 112: 181−186. doi: 10.1016/j.amjcard.2013.03.012
|
[6] |
De Luca G, van't Hof AW, Huber K, et al. Impact of advanced age on myocardial perfusion, distal embolization, and mortality patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein Ⅱb-Ⅲa inhibitors. Heart Vessels 2014; 29: 15−20. doi: 10.1007/s00380-013-0323-4
|
[7] |
De Luca G, Suryapranata H, Ottervanger JP, et al. Comparison between stenting and balloon in elderly patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Int J Cardiol 2007; 119: 306−309. doi: 10.1016/j.ijcard.2006.07.143
|
[8] |
Savonitto S, Cavallini C, Petronio AS, et al. Early aggressive versus initially conservative treatment in elderly patients with non-ST-segment elevation acute coronary syndrome: a randomized controlled trial. JACC Cardiovasc Interv 2012; 5: 906−916. doi: 10.1016/j.jcin.2012.06.008
|
[9] |
Tegn N, Abdelnoor M, Aaberge L, et al. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet 2016; 387: 1057−1065. doi: 10.1016/S0140-6736(15)01166-6
|
[10] |
Morici N, Savonitto S, Biondi-Zoccai G, De Servi S. Invasive management for elderly adults with acute coronary syndrome: where are we now? J Am Geriatr Soc 2016; 64: 2396−2397. doi: 10.1111/jgs.14466
|
[11] |
Jones CI. Platelet function and ageing. Mamm Genome 2016; 27(7-8): 358−366. doi: 10.1007/s00335-016-9629-8
|
[12] |
Dayal S, Wilson KM, Motto DG, et al. Hydrogen peroxide promotes aging-related platelet hyperactivation and thrombosis. Circulation 2013; 127: 1308−1316. doi: 10.1161/CIRCULATIONAHA.112.000966
|
[13] |
Cowman J, Dunne E, Oglesby I, et al. Age-related changes in platelet function are more profound in women than in men. Sci Rep 2015; 5: 12235. doi: 10.1038/srep12235
|
[14] |
Segal JB. Moliterno AR (2006) Platelet counts differ by sex, ethnicity, and age in the United States. Ann Epidemiol 2006; 16: 123−130. doi: 10.1016/j.annepidem.2005.06.052
|
[15] |
Verdoia M, Nardin M, Negro F, et al. Impact of aging on immature platelet count and its relationship with coronary artery disease. Platelets 2020; 31: 1060−1068. doi: 10.1080/09537104.2020.1714572
|
[16] |
Verdoia M, Schaffer A, Barbieri L, et al. Impact of age on mean platelet volume and its relationship with coronary artery disease: a single-centre cohort study. Exp Gerontol 2015; 62: 32−36. doi: 10.1016/j.exger.2014.12.019
|
[17] |
Verdoia M, Pergolini P, Nardin M, et al. Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy. J Thromb Thrombolysis 2019; 48: 413−421. doi: 10.1007/s11239-019-01873-2
|
[18] |
Calabrò P, Moscarella E, Gragnano F, et al. Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). Am J Cardiol 2019; 124: 1662−1668. doi: 10.1016/j.amjcard.2019.08.030
|
[19] |
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001−2015. doi: 10.1056/NEJMoa0706482
|
[20] |
Savonitto S, Ferri LA, Piatti L, et al. Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization. Circulation 2018; 137: 2435−2445. doi: 10.1161/CIRCULATIONAHA.117.032180
|
[21] |
Elliot Cham B, Dykman JH, Bochner F. Urinary excretion of aspirin. Br J Clin Pharmacol 1982; 14: 562−564. doi: 10.1111/j.1365-2125.1982.tb02030.x
|
[22] |
Airoldi G, Campanini M. Prasugrel. Italian Journal of Medicine 2013; 4: 43−50.
|
[23] |
Zhang YJ, Li MP, Tang J, Chen XP. Pharmacokinetic and pharmacodynamic responses to clopidogrel: evidences and perspectives. Int J Environ Res Public Health 2017; 14: 301. doi: 10.3390/ijerph14030301
|
[24] |
De Rosa R, Piscione F, Galasso G, et al. Antiplatelet therapy in very elderly and comorbid patients with acute coronary syndromes. J Geriatr Cardiol 2019; 16: 103−113.
|
[25] |
Zaman MJ, Stirling S, Shepstone L, et al. The association between older age and receipt of care and outcomes in patients with acute coronary syndromes: a cohort study of the Myocardial Ischaemia National Audit Project (MINAP). Eur Heart J 2014; 35: 1551−1558. doi: 10.1093/eurheartj/ehu039
|
[26] |
Avezum A, Makdisse M, Spencer F, Gore JM, Fox KA, Montalescot G, Eagle KA, White K, Mehta RH, Knobel E, Collet JP; GRACE Investigators. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2005; 149(1): 67−73. doi: 10.1016/j.ahj.2004.06.003
|
[27] |
Szummer K, Montez-Rath ME, Alfredsson J, et al. Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome: insights from the SWEDEHEART Registry. Circulation 2020; 142: 1700−1708. doi: 10.1161/CIRCULATIONAHA.120.050645
|
[28] |
Husted S, James S, Becker RC, et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 2012; 5: 680−688. doi: 10.1161/CIRCOUTCOMES.111.964395
|
[29] |
Kaul P, Alexander KP, Ohman EM, et al. Sex and prognostic significance of self-reported frailty in non-st-segment elevation acute coronary syndromes: insights from the TRILOGY ACS trial. Can J Cardiol 2019; 35: 430−437. doi: 10.1016/j.cjca.2018.12.035
|
[30] |
Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet 2020; 395: 1374−1381. doi: 10.1016/S0140-6736(20)30325-1
|
[31] |
Gremmel T, Steiner S, Seidinger D, et al. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J Thromb Haemost 2010; 8: 37−42. doi: 10.1111/j.1538-7836.2009.03644.x
|
[32] |
Silvain J, Cayla G, Hulot JS, Finzi J, et al. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. Eur Heart J 2012; 33: 1241−1249. doi: 10.1093/eurheartj/ehr407
|
[33] |
Verdoia M, Pergolini P, Rolla R, et al. Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. J Thromb Haemost 2016; 14: 57−64. doi: 10.1111/jth.13177
|
[34] |
Alexopoulos D, Xanthopoulou I, Storey RF, et al. Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. Am Heart J 2014; 168: 530−536. doi: 10.1016/j.ahj.2014.06.026
|
[35] |
Crimi G, Morici N, Ferrario M, et al. Time course of ischemic and bleeding burden in elderly patients with acute coronary syndromes randomized to low-dose prasugrel or clopidogrel. J Am Heart Assoc 2019; 8: e010956.
|
[36] |
De Luca G, Damen SA, Camaro C, et al. Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). EuroIntervention 2019; 15: e990−e998. doi: 10.4244/EIJ-D-19-00539
|
[37] |
Verdoia M, Kedhi E, Suryapranata H, et al. Benefits of short-term or prolonged as compared to standard 1 year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials. J Thromb Thrombolysis 2020; 50: 337−354. doi: 10.1007/s11239-019-02033-2
|
[38] |
Naber CK, Urban P, Ong PJ, et al. Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study. Eur Heart J 2017; 38: 961−969.
|
[39] |
Varenne O, Cook S, Sideris G, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet 2018; 391: 41−50. doi: 10.1016/S0140-6736(17)32713-7
|
[40] |
Kupka D, Sibbing D. De-Escalation of P2Y12 receptor inhibitor therapy after acute coronary syndromes in patients undergoing percutaneous coronary intervention. Korean Circ J 2018; 48: 863−872. doi: 10.4070/kcj.2018.0255
|
[41] |
Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 2017; 38: 3070−3078. doi: 10.1093/eurheartj/ehx175
|
[42] |
Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 2017; 390: 1747−1757. doi: 10.1016/S0140-6736(17)32155-4
|
[43] |
Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med 2019; 381: 1621−1631. doi: 10.1056/NEJMoa1907096
|
[44] |
Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 2016; 388: 2015−2022. doi: 10.1016/S0140-6736(16)31323-X
|
[45] |
Nikolsky E, Stone GW, Kirtane AJ, et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009; 54: 1293−1302. doi: 10.1016/j.jacc.2009.07.019
|
[46] |
Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 2019; 381: 2032−2042. doi: 10.1056/NEJMoa1908419
|
[47] |
Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs. aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 2018; 392: 940−949. doi: 10.1016/S0140-6736(18)31858-0
|
[48] |
Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA 2020; 323: 2407−2416. doi: 10.1001/jama.2020.7580
|
[49] |
Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial. JAMA 2019; 321: 2414−2427. doi: 10.1001/jama.2019.8145
|
[50] |
Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 380: 1509−1524. doi: 10.1056/NEJMoa1817083
|
[51] |
Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375: 2423−2434. doi: 10.1056/NEJMoa1611594
|
[52] |
Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2020. Published online first: Aug 29, 2020. DOI: 10.1093/eurheartj/ehaa575.
|
[53] |
Montalto C, Crimi G, Morici N, et al. Bleeding risk prediction in elderly patients managed invasively for acute coronary syndromes: External validation of the PRECISE-DAPT and PARIS scores. Int J Cardiol 2021; 328: 22−28. doi: 10.1016/j.ijcard.2020.11.065
|
[54] |
Guerrero C, Ariza-Solé A, Formiga F, et al. Applicability of the PRECISE-DAPT score in elderly patients with myocardial infarction. J Geriatr Cardiol. 2018; 15: 713−717.
|
[55] |
The British Heart Foundation; https://clinicaltrials.gov/ct2/show/NCT03052036;
|
[56] |
European Cardiovascular Research Center; https://www.clinicaltrials.gov/ct2/show/NCT03023020 (accessed March 22nd 2021).
|